Probability of disease progression (interval from diagnosis to initiation of chemotherapy) in 10 patients with HLA-G-positive and 37 patients with HLA-G-negative B-CLL. Kaplan-Meier analysis. The median progression-free survival time was 23 months in HLA-G-positive and 120 months in HLA-G-negative B-CLL (P = .0001, log-rank test). All patients with HLA-G-positive B-CLL received chemotherapy within 42 months.